Bendamustine-induced rash is associated with a favorable prognosis in patients with indolent B-cell lymphoma

Bendamustine is now recognized as a key drug for indolent B-cell lymphoma (iBCL), mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). Skin toxicity associated with bendamustine is one of the characteristic adverse effects. We retrospectively examined the relationship between bendamust...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Naoki, Tsukasaki, Kunihiro, Tanae, Ken, Kohri, Mika, Asou, Chie, Okamura, Daisuke, Ishikawa, Maho, Maeda, Tomoya, Kawai, Nobutaka, Matsuda, Akira, Sato, Tsugumi, Kayano, Hidekazu, Arai, Eiichi, Asou, Norio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JSLRT 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010495/
https://www.ncbi.nlm.nih.gov/pubmed/34980789
http://dx.doi.org/10.3960/jslrt.21018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010495/
https://www.ncbi.nlm.nih.gov/pubmed/34980789
http://dx.doi.org/10.3960/jslrt.21018

Ejemplares similares